Table 2.
Genotype Distributions and Allelic Frequencies of Single-Nucleotide Polymorphisms in EGF and EGFR
| Gene | SNPs | Genotype/allele | Case | Control | χ2 | p/p* | OR | 95% CI |
|---|---|---|---|---|---|---|---|---|
| EGFR | rs2072454 | n=410 (%) | n=634 (%) | |||||
| CC | 158 (38.5) | 196 (30.9) | 6.48 | 0.039/0.143 | 1.21 | 0.94–1.56 | ||
| CT | 185 (45.1) | 319 (50.3) | ||||||
| TT | 67 (16.3) | 119 (18.8) | ||||||
| C | 501 (61.1) | 711 (56.1) | 5.16 | 0.023 | 1.23 | 1.02–1.48 | ||
| T | 319 (38.9) | 557 (43.9) | ||||||
| rs2227983 | n=402 (%) | n=643 (%) | ||||||
| AA | 113 (28.1) | 170 (26.4) | 1.75 | 0.416/0.184 | 1.19 | 0.92–1.54 | ||
| GA | 205 (51.0) | 316 (49.1) | ||||||
| GG | 84 (20.9) | 157 (24.4) | ||||||
| A | 431 (53.6) | 656 (51.0) | 1.34 | 0.248 | 1.11 | 0.93–1.33 | ||
| G | 373 (46.4) | 630 (49.0) | ||||||
| rs17337023 | n=393 (%) | n=631 (%) | ||||||
| AA | 119 (30.3) | 169 (26.8) | 1.55 | 0.462/0.155 | 1.21 | 0.93–1.58 | ||
| TA | 196 (49.9) | 335 (53.1) | ||||||
| TT | 78 (19.8) | 127 (20.1) | ||||||
| A | 434 (55.2) | 673 (53.3) | 0.70 | 0.404 | 1.08 | 0.90–1.30 | ||
| T | 352 (44.8) | 589 (46.7) | ||||||
| rs1050171 | n=412 (%) | n=638 (%) | ||||||
| AA | 14 (3.4) | 19 (3.0) | 1.35 | 0.256/0.115 | 0.76 | 0.56–1.07 | ||
| GA | 118 (28.6) | 164 (25.7) | ||||||
| GG | 280 (68.0) | 455 (71.3) | ||||||
| A | 146 (17.7) | 202 (15.8) | 1.29 | 0.510 | 1.14 | 0.91–1.45 | ||
| G | 678 (82.3) | 1074 (84.2) | ||||||
| rs2293347 | n=406 (%) | n=640 (%) | ||||||
| AA | 37 (9.1) | 60 (9.4) | 0.33 | 0.850/0.478 | 1.10 | 0.84–1.45 | ||
| GA | 176 (43.3) | 266 (41.6) | ||||||
| GG | 193 (47.6) | 314 (49.0) | ||||||
| A | 250 (30.8) | 386 (30.2) | 0.09 | 0.759 | 1.03 | 0.85–1.25 | ||
| G | 562 (69.2) | 894 (69.8) | ||||||
| rs884225 | n=415 (%) | n=643 (%) | ||||||
| AA | 112 (27.0) | 147 (22.9) | 2.50 | 0.286/0.194 | 1.18 | 0.92–1.52 | ||
| GA | 206 (49.6) | 330 (51.3) | ||||||
| GG | 97 (23.4) | 166 (25.8) | ||||||
| A | 430 (51.8) | 624 (48.5) | 2.18 | 0.140 | 1.14 | 0.96–1.36 | ||
| G | 400 (48.2) | 662 (51.5) | ||||||
| EGF | rs11569017 | n=411 (%) | n=636 (%) | |||||
| TT | 15 (3.6) | 16 (2.5) | 10.53 | 0.005/0.021 | 1.48 | 1.06–2.07 | ||
| TA | 142 (34.5) | 166 (26.1) | ||||||
| AA | 254 (61.8) | 454 (71.4) | ||||||
| T | 172 (20.9) | 198 (15.6) | 9.86 | 0.001 | 1.43 | 1.15–1.79 | ||
| A | 650 (79.1) | 1074 (84.4) | ||||||
| rs4444903 | n=404 (%) | n=623 (%) | ||||||
| AA | 45 (11.1) | 76 (12.2) | 1.80 | 0.407/0.706 | 0.95 | 0.735–1.23 | ||
| AG | 153 (37.9) | 256 (41.1) | ||||||
| GG | 206 (51.0) | 291 (46.7) | ||||||
| A | 243 (30.1) | 408 (32.7) | 1.61 | 0.204 | 0.88 | 0.73–1.07 | ||
| G | 565 (69.9) | 838 (67.3) |
Cases: patients with HBV-related HCC.
Controls: individuals who had never been infected with HBV and in whom all HBV serum markers were negative.
p*, p-Value conducted by binary logistic regression to determine age and gender for susceptibility to HCC under an additive model.
OR, odds ratio; CI, confidence interval; df=2; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.